UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
GENOMICS & PRECISION MEDICINE

Eurofins Scientific

E

Eurofins Scientific

Genomics & Precision MedicineLuxembourg City, Luxembourg
Visit Website

About Eurofins Scientific

Eurofins Scientific is one of the world's largest networks of independent laboratories, offering an exceptionally broad range of testing, bioanalytical, and discovery services to the pharmaceutical, food, environmental, and consumer products industries. Founded in 1987 in Nantes, France, the company has grown from a specialist in food authenticity testing into a global life science services powerhouse, now operating more than 900 laboratories across over 60 countries.

Pharmaceutical & Bioanalytical Testing Services

Within the pharmaceutical sector, Eurofins provides contract testing services spanning the full drug development and manufacturing lifecycle. Its offerings include physicochemical analysis, microbiology and sterility testing, stability studies, method development and validation, and raw material testing. The company also operates a significant bioanalytical division, supporting clinical trials through regulated bioanalysis, pharmacokinetics, and immunogenicity testing. These capabilities make it a widely used partner for both large pharmaceutical companies and emerging biotech firms seeking outsourced laboratory expertise.

Genomics, CDMO Support & Discovery Sciences

Eurofins has built a substantial presence in genomics services, including DNA sequencing, genotyping, gene synthesis, and next-generation sequencing, operating through its dedicated Eurofins Genomics brand. The group also supports CDMO partners and sponsors with quality control testing for biologics, biosimilars, and advanced therapy medicinal products. Its discovery sciences arm offers screening, ADME-Tox, and in vitro pharmacology services, enabling earlier-phase research outsourcing alongside its late-stage and commercial manufacturing quality work.

Listed on Euronext Brussels under the ticker ERF, Eurofins is headquartered in Luxembourg and operates with revenues that place it firmly among the leading life science services groups globally. Its decentralised laboratory network is a deliberate structural choice, allowing local regulatory expertise and rapid service delivery alongside the scale benefits of a multinational organisation. The company serves clients across agrochemical, environmental, forensic, and clinical diagnostics sectors in addition to its core pharmaceutical audience.

Further information is available at eurofins.com.

Similar Companies

More in Genomics & Precision Medicine

A

Alkahest

Mining what it describes as the deepest layers of plasma knowledge, Alkahest combines artificial intelligence, multiomics analysis and real-world data with deep plasma protein expertise to drive drug discovery. A subsidiary of Grifols, the California-based research company focuses on identifying and developing transformative therapies derived from the science of plasma. The scientific foundation underlying Alkahest's pipeline rests on the premise that the plasma proteome is in constant flux, influencing human biology in ways that can both sustain and undermine health. According to the company, alterations in plasma protein concentration and conformation are linked to multiple drivers of disease, with changes appearing years before clinical diagnosis. This positions plasma proteins as potential early biomarkers capable of informing prediction, diagnosis and treatment. A significant competitive asset is access to Grifols' plasma repository, which the company describes as one of the world's largest collections, comprising more than 100 million plasma samples gathered over nearly 15 years. The dataset spans thousands of disease states and is linked to real-world health records. Alkahest applies advanced analytical and integrative multiomics capabilities to this resource to build an evolving picture of the protein network and its relationship to human ageing and disease. The company's work sits at the intersection of plasma biology, data science and therapeutic development, representing a scientifically grounded approach to conditions where conventional small-molecule or antibody strategies have faced limitations. Further information is available at alkahest.com.

View profile
Q

QIAGEN

QIAGEN pioneered the column-based nucleic acid purification method that became the global standard for molecular biology, and today its sample-to-insight technologies are used in more than 500,000 laboratories across 160 countries. Founded in 1984 in Düsseldorf, Germany, and listed on both the Nasdaq and the Frankfurt Stock Exchange under the ticker QGEN, the company occupies a singular position in life sciences: it sits at the very front of the analytical workflow, ensuring that the biological sample reaching any downstream instrument is clean, consistent, and ready for meaningful results. Sample Technologies & Molecular Diagnostics The company's portfolio spans consumables, automated instruments, and bioinformatics, unified by the principle that sample quality determines everything that follows. Its QIAamp, RNeasy, and DNeasy product families are reference standards in research and clinical settings alike. The QIAsymphony and QIAcube platforms automate extraction workflows from research benches through to hospital laboratories, reducing hands-on time and variability. In molecular diagnostics, QIAGEN markets CE-marked and FDA-cleared assays covering infectious disease detection, oncology companion diagnostics, and human identification, with the QIAstat-Dx syndromic testing system enabling rapid, near-patient panel testing for respiratory and gastrointestinal pathogens. Bioinformatics & Precision Medicine Through its QIAGEN Digital Insights division, the company provides bioinformatics software that connects raw sequencing output to clinical and biological interpretation. Ingenuity Pathway Analysis and the CLC Genomics Workbench are widely used in both pharmaceutical research and translational medicine. The QCI Interpret platform supports variant classification for oncology and rare-disease workflows, positioning QIAGEN as a partner across the continuum from discovery research to regulated diagnostics. Therapy areas served include oncology, infectious disease, immunology, and forensics, with a growing presence in liquid biopsy and companion diagnostic development for pharmaceutical partners. Headquartered in Venlo, Netherlands, with operational hubs in Hilden, Germany, and Germantown, Maryland, QIAGEN employs approximately 6,000 people worldwide and generates revenues in excess of two billion US dollars annually. The company serves customers in pharmaceuticals, biotechnology, clinical diagnostics, applied testing, and academic research. Further information is available at qiagen.com.

View profile
A

ACM Global Laboratories

ACM Global Laboratories operates across four continents, delivering central laboratory services, bioanalysis, and toxicology to sponsors running clinical trials at every stage of development. With facilities in Rochester (NY), York (UK), Singapore, and Mumbai, the organisation functions as a single integrated laboratory network rather than a collection of regional outposts, giving study teams a consistent standard of science regardless of trial geography. Central Lab and Bioanalytical Capabilities The central lab division handles routine safety testing, biomarker testing, flow cytometry, radiopharmaceutical services, and pathology, alongside the full spectrum of clinical trial testing. Sponsors with urgent timelines can access dedicated rescue and expedite study pathways, reducing the risk that slow laboratory turnaround becomes the critical path on a programme. Sample logistics are supported by customised collection kits and advanced sample tracking, which simplifies the co-ordination burden for site staff and CRO project managers alike. The bioanalytical services portfolio covers large molecule bioanalysis, advanced pharmacokinetic bioanalysis, pharmacodynamic biomarker analysis, controlled substance analysis, and work on novel drug delivery systems. Specialist capability extends to nicotine research and cannabinoid testing, areas that require particular regulatory sensitivity. COVID-19 research studies are also accommodated within the central lab offering. Toxicology and Workplace Testing The toxicology division provides drug monitoring, workplace testing, and reference laboratory testing, serving both clinical development programmes and occupational health requirements. This breadth makes ACM Global Laboratories relevant to pharmaceutical, biotech and corporate clients whose needs span the regulated and non-regulated sectors. Client-facing resources include a self-service portal, the ACM QuikReport tool, and LabStar, a platform that supports site training and sample management. The combination of these digital tools with a global physical footprint positions the organisation well for decentralised and hybrid trial designs that are now common across the industry. ACM marks fifty years of operation, a milestone that underscores the depth of institutional experience behind its service model. Further information is available at acmgloballab.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy